Rising Prevalence of Gastric Disorders propelling the growth of the Gastroretentive Drug Delivery Systems Market

Published: Jul 2021

The global gastroretentive drug delivery systems market is anticipated to grow at a CAGR of around 6.3% during the forecast period (2021-2027). The rising prevalence of functional gastrointestinal disorders (FGIDs), and gastric disorders majorly among the geriatric population globally is the major factor augmenting the growth of the gastroretentive drug delivery systems. The aged population is more susceptible to long-standing conditions such as dyspepsia, irritable bowel syndrome, inflammatory bowel disease (Crohn’s disease and ulcerative colitis), celiac disease, and GERD due to the weak immune system and aging factor. Whereas the increasing prevalence of gastric cancer is also the factor due to which the adoption of advanced drug delivery systems is gaining popularity. Among major economies, the US is the region with a large presence of people affected with gastric cancer, and this burden is increasing at an alarming rate. According to the American Cancer Society’s estimates, in 2021, in the US, there were 26,560 new cases of stomach cancer were found, among which 16,160 were in men, and 10,400 were in women. Due to increased cases of gastric cancer, and other gastric disorders, the key players are focusing on investing high expenditure on the development of new and advanced drug delivery systems. 

Browse the full report description of "Global Gastroretentive Drug Delivery Systems Market Size, Share & Trends Analysis Report By Type (High-Density Systems, Expandable Drug Delivery Systems, Bioadhesive Drug Delivery Systems, Floating Drug Delivery Systems and Others) By Dosage Forms (Tablets, Liquid, Microspheres, Capsule, and Others) By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast, 2021-2027" at https://www.omrglobal.com/industry-reports/gastroretentive-drug-delivery-systems-market

Moreover, the rapid development in healthcare infrastructure, an increasing number of hospitals and online pharmacies across the regions, and development in drug delivery systems are also the prominent factors contributing to driving the market growth. 

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered- 

o By Type

o By Dosage Forms

o By Distribution Channel

  • Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

  • Competitive Landscape- F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Ltd., GlaxoSmithKline PLC, Assertio Holdings, Inc., Alcon Vision LLC, Lupin, Pfizer Inc., and others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominate the market in the base year?
  • Which segment and region will project the fastest growth in the market?
  • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How are players addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Gastroretentive Drug Delivery Systems Market Report Segment

By Type

  • High-Density Systems
  • Expandable Drug Delivery Systems
  • Bioadhesive Drug Delivery Systems
  • Floating Drug Delivery Systems
  • Others

By Dosage form

  • Capsule
  • Microspheres
  • Tablets
  • Liquid
  • Others

By Distribution Channel

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Global Gastroretentive Drug Delivery Systems Market Report by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World

  • Latin America 
  • Middle East & Africa

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/gastroretentive-drug-delivery-systems-market